B12 deficiency impairs FA -oxidation in mature human ATs and its association with serum B12 Similar to lipogenesis, we further validated the expression of genes involved in FAO in AT
The compound's name explicitly reflects its intended indication: an anti-obesity agent designed to selectively activate the lipolytic (fat-burning) properties of growth hormone while eliminating the growth-promoting and glucose-dysregulating effects associated with intact GH
A separate product, semaglutide subcutaneous injection (Wegovy), is indicated as an adjunct to lifestyle modifications for weight loss and chronic weight management in obese (BMI 30 kg/m2 or greater) or overweight adults (BMI 27 kg/m2 or greater) with at least 1 weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
For trial details see the Motus study
Please contact Genesis Lifestyle Medicine to determine if you can benefit from LipoLEAN injections
Still workable but tighter